TNFRSF4 and breast carcinoma: Nanoparticles that spatio-temporally delivered anti-PD-1 checkpoint inhibitors and agonistic anti-OX40 antibodies simultaneously to mouse 4T1 breast cancer significantly elevated T-cell stimulation via enhanced release of IFN-γ and increased CD8+:Treg cell ratio, resulting in doubling of survival rates (141).